{"id":400942,"date":"2020-12-16T09:03:34","date_gmt":"2020-12-16T14:03:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400942"},"modified":"2020-12-16T09:03:34","modified_gmt":"2020-12-16T14:03:34","slug":"triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/","title":{"rendered":"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope"},"content":{"rendered":"
\n

VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) — TRIUMF<\/a>, Canada\u2019s particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc.<\/a> (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to\u00a0actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies.<\/p>\n

An alpha-emitting isotope with a short half-life, actinium-225 can be combined with a molecular agent that specifically targets cancer cells, seeking out and destroying the cancer while leaving the surrounding tissue unharmed.\u00a0The new collaboration will enable TRIUMF to significantly increase its production and delivery of actinium-225.<\/p>\n

\u201cToday\u2019s announcement marks an important step in positioning Canada to play a leading role in the development and deployment of next-generation radiotherapies, and in ensuring that researchers and patients around the world have a stable supply of life-saving medical isotopes,\u201d said Dr. Jonathan Bagger, Director of TRIUMF.<\/strong> \u201cEnabled by decades of public investment in TRIUMF\u2019s infrastructure and research programs, this collaboration recognizes the laboratory\u2019s capacity to drive innovation, moving this promising treatment closer to market.\u201d<\/p>\n

\u201cGiven Fusion\u2019s opportunity to expand our pipeline of actinium-based Targeted Alpha Therapies (TATs), and the importance of isotope production in the supply chain of radiopharmaceuticals, we will continue to proactively address and prioritize actinium supply in our strategic plans,\u201d said Dr.<\/strong>John Valliant, Chief Executive Officer of Fusion<\/strong>. \u201cWe are excited to collaborate with TRIUMF, a leader in isotope production, as part of these plans.\u201d<\/p>\n

\u201cWith its Targeted Alpha Therapy platform technology, Fusion has an opportunity to impact the cancer treatment landscape,\u201d said Kathryn Hayashi, Chief Executive Officer of TRIUMF Innovations<\/strong>. \u201cThrough this collaboration agreement, we are partnering with a premier developer of innovative radiotherapies to deepen TRIUMF\u2019s leadership position in isotope production to help save the lives of patients in Canada and around the world\u201d.<\/p>\n

Read more about the announcement here<\/a>.<\/p>\n

\n About TRIUMF<\/strong>
\n
\n TRIUMF<\/a>\u00a0is Canada\u2019s particle accelerator\u00a0centre. The lab is a hub for discovery and innovation, inspired by a half-century of ingenuity in answering some of nature\u2019s most challenging questions. From the hunt for the smallest particles in the universe to the development of new technologies, TRIUMF is pushing frontiers in research, while training the next generation of leaders in science, medicine, and business. Learn more about TRIUMF\u2019s work to produce more actinium-225 here<\/a>.<\/p>\n

Discover more at\u00a0www.triumf.ca<\/a>\u00a0and connect on Facebook, Twitter, and Instagram: @TRIUMFLab.<\/p>\n

\n About TRIUMF Innovations<\/strong>
\n
TRIUMF Innovations Inc. is TRIUMF\u2019s business interface and commercialization arm, connecting Canada\u2019s particle accelerator centre to the private sector via industry partnerships, licensing, and company creation. TRIUMF Innovations provides pathways for businesses to access the expertise and infrastructure at TRIUMF and across the TRIUMF network.<\/p>\n

Learn more at\u00a0www.triumfinnovations.ca<\/a>\u00a0and connect on Twitter at @TRIUMFInno.<\/p>\n

\n Media Contact:<\/strong>
\n
Kamran Shaikh
PR Associates
7788465406
kshaikh@prassociates.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) — TRIUMF, Canada\u2019s particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to\u00a0actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies. An alpha-emitting isotope with a short half-life, actinium-225 can be combined with a molecular agent that specifically targets cancer cells, seeking out and destroying the cancer while leaving the surrounding tissue unharmed.\u00a0The new collaboration will enable TRIUMF to significantly increase its … <\/p>\n

Continue reading “TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400942","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) — TRIUMF, Canada\u2019s particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to\u00a0actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies. An alpha-emitting isotope with a short half-life, actinium-225 can be combined with a molecular agent that specifically targets cancer cells, seeking out and destroying the cancer while leaving the surrounding tissue unharmed.\u00a0The new collaboration will enable TRIUMF to significantly increase its … Continue reading "TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T14:03:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope\",\"datePublished\":\"2020-12-16T14:03:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/\"},\"wordCount\":515,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/\",\"name\":\"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==\",\"datePublished\":\"2020-12-16T14:03:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/","og_locale":"en_US","og_type":"article","og_title":"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope - Market Newsdesk","og_description":"VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) — TRIUMF, Canada\u2019s particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to\u00a0actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies. An alpha-emitting isotope with a short half-life, actinium-225 can be combined with a molecular agent that specifically targets cancer cells, seeking out and destroying the cancer while leaving the surrounding tissue unharmed.\u00a0The new collaboration will enable TRIUMF to significantly increase its … Continue reading \"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T14:03:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope","datePublished":"2020-12-16T14:03:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/"},"wordCount":515,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/","name":"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==","datePublished":"2020-12-16T14:03:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjk1NCMzODgzNTY3IzUwMDA3NjQ2NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/triumf-enters-collaboration-with-fusion-pharmaceuticals-to-boost-production-of-actinium-225-a-cancer-fighting-medical-isotope\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400942"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400942\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}